{
    "clinical_study": {
        "@rank": "35307", 
        "arm_group": [
            {
                "arm_group_label": "TAK-233", 
                "arm_group_type": "Experimental", 
                "description": "Oral administration"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Oral administration"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this clinical trial is to examine the clinical pharmacology properties of\n      TAK-233 in  healthy female subjects"
        }, 
        "brief_title": "A Phase I Clinical Pharmacology Study of TAK-233 in Healthy Subjects", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Clinical Pharmacology", 
        "detailed_description": {
            "textblock": "The primary objective of this study is to examine the pharmacodynamics and the safety of\n      TAK-233 administered as a single dose in healthy women."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subjects who understand the contents of this clinical trial and who the investigator\n             or sub-investigator consider able to comply with the procedures of the clinical trial\n\n          2. Subjects who can sign the informed consent form and can date the form without\n             assistance before starting the procedures of the clinical trial\n\n          3. Healthy Japanese women\n\n          4. Subjects aged \u2265 20 and \u2264 40 years at the time of consent\n\n          5. Subjects with body weight \u2265 45 kg and BMI \u226518.5 and \u2264 25.0 kg/m2 at the time of\n             screening\n\n          6. Women of child bearing potential who agree to take specified contraceptive measures\n             regularly from the time of consent until 4 weeks after the end of the last assessment\n             in the fourth treatment period\n\n        Exclusion Criteria:\n\n          1. Subjects who received TAK-233 within 16 weeks before the start of initial\n             administration\n\n          2. Subjects who have previously received TAK-233 during treatment or during\n             participation in another clinical trial\n\n          3. Employees of the medical institution conducting this clinical trial and their\n             family/dependents (e.g., husband or wife, parents, children, and siblings), or\n             subjects who may be coerced to agree to participate in the clinical trial\n\n          4. Subjects with poorly controlled and clinically significant neurological,\n             cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal (including\n             chronic costiveness), urological (including dysuria), autoimmune, endocrine, or\n             psychiatric diseases or other abnormalities which may affect the subject's\n             participation in the clinical trial or results of the clinical trial\n\n          5. Subjects with hypersensitivity to TAK-233 related substances, or excipients of these\n             products\n\n          6. Subjects whose urine tested positive for drug abuse at screening\n\n          7. Subjects with a history of drug abuse (defined as the use of illegal drugs) or\n             alcohol dependence within 52 weeks before the screening assessments, or subjects who\n             are not willing to stop alcohol intake or drug use during their participation in the\n             clinical trial\n\n          8. Subjects who need to take prohibited concomitant medications, vitamins, or foods\n             listed in listed in what?\n\n          9. Pregnant or lactating women, women expecting to be pregnant before giving consent,\n             during this clinical trial, or within 4 weeks after the completion of this clinical\n             trial, or women who are planning to donate their ova during this period\n\n         10. Subjects with currently active cardiovascular diseases, central nervous system\n             diseases, hepatic diseases, hematopoietic diseases, renal failure, metabolic\n             disorders, endocrine disorders, serious allergies, asthma, hypoxemia, hypertension,\n             convulsion, allergic exanthema, or urological disorders (subjects with peptic ulcer,\n             convulsive disorders, or arrhythmia also fall this category)\n\n         11. Subjects that have any of the following diseases/surgical interventions that may\n             affect drug absorption: digestive system disorders (malabsorption, esophageal reflux,\n             peptic ulcer, erosive oesophagitis, frequent heartburn (at least once a week), or\n             surgical interventions (e.g., cholecystectomy), or subjects who have had prior\n             history of any of these diseases/surgical interventions within the last 24 weeks\n\n         12. Subjects with a history of cancer (excluding subjects whose basal cell carcinoma has\n             been in remission for at least 5 years\n\n         13. Subjects that have tested positive for hepatitis B surface antigen (HBsAg), hepatitis\n             C virus (HCV) antibody, human immunodeficiency virus (HIV) antigen/antibody, or\n             syphilis serological reaction at screening\n\n         14. Subjects who took nicotine-containing products (e.g., cigarette, pipe tobacco, cigar,\n             chewing tobacco, nicotine patch, and nicotine gum) within 28 days before\n             hospitalization\n\n         15. Subjects for whom blood collection from peripheral veins is difficult\n\n         16. Subjects who donated at least 200 mL of whole blood within 4 weeks before the start\n             of the initial administration, or subjects who donated at least 400 mL of whole blood\n             within 16 weeks before the start of the initial administration\n\n         17. Subjects who donated at least 400 mL (in total) of whole blood within 52 weeks before\n             the start of the initial administration\n\n         18. Subjects who donated blood components within 2 weeks before the start of the initial\n             administration\n\n         19. Subjects with clinically significant abnormalities on the electrocardiogram recorded\n             at screening or hospitalization (Day -1 of the first treatment period)\n\n         20. Subjects who had a QTcF interval of > 470 msec or a PR interval of < 120 msec or >\n             220 msec on the electrocardiogram recorded at screening or hospitalization\n\n         21. Subjects with a systolic blood pressure of < 100 mmHg or > 140 mmHg and a diastolic\n             blood pressure of < 60 mmHg or > 90 mmHg at screening or hospitalization\n\n         22. Subjects with a heart rate of < 50 bpm or > 90 bpm at screening or hospitalization\n\n        22. Subjects unlikely to comply with the protocol, or subjects the investigator or\n        sub-investigator considers ineligible for participation in the clinical trial due to other\n        reasons"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02113020", 
            "org_study_id": "TAK-233/CPH-003", 
            "secondary_id": "U1111-1152-9381"
        }, 
        "intervention": [
            {
                "arm_group_label": "TAK-233", 
                "description": "Oral administration of TAK-233", 
                "intervention_name": "TAK-233", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Oral admininstration of Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 9, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kumamoto-shi", 
                    "country": "Japan", 
                    "state": "Kumamoto"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "medicalinformation@tpna.com", 
            "last_name": "Takeda Study Registration Call Center", 
            "phone": "+81-6-6204-5883"
        }, 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "General Manager", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from baseline in motor threshold for urethral sphincter contraction.", 
                "safety_issue": "No", 
                "time_frame": "0.5 hours post-dose"
            }, 
            {
                "measure": "Change from baseline in motor threshold for urethral sphincter contraction.", 
                "safety_issue": "No", 
                "time_frame": "3 hours post-dose"
            }, 
            {
                "measure": "Change from baseline in motor threshold for urethral sphincter contraction.", 
                "safety_issue": "No", 
                "time_frame": "6 hours post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02113020"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Treatment emergent adverse events, vital signs, weight, safety ECG, and clinical laboratory tests (hematology, serum chemistry, and urinalysis).", 
            "measure": "Number of participants with adverse events", 
            "safety_issue": "No", 
            "time_frame": "Up to 28 days"
        }, 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}